Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar, bevacizumab) for Wet Age-Related Macular Degeneration

 Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar, bevacizumab) for Wet Age-Related Macular Degeneration

Shots:

  • The first patient has been dosed in a P-I study of HLX04-O conducting in patients with wAMD. The primary objective of the study is to evaluate the safety & tolerability of HLX04-O in 6-12 patients with wAMD
  • The secondary objective of the study is to evaluate the PK profiles of HLX04-O after intravitreal injection
  • In Oct’2020, Henlius signed co-development and exclusive license agreement with Essex. The companies plan to conduct clinical trials of HLX04-O in China, Australia, EU, and the US, and apply marketing authorization in different countries and regions across the globe

Click here to read full press release/ article | Ref: Henlius | Image: nature

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post